Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.74 |
| ▸ | F12 | P00748 | 1/20 | 0.74 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.74 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.74 |
| ▸ | F2 | P00734 | 1/20 | 0.71 |
| ▸ | C1R | P00736 | 1/20 | 0.71 |
| ▸ | F10 | P00742 | 1/20 | 0.71 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.71 |
| ▸ | KLK1 | P06870 | 1/20 | 0.71 |
| ▸ | PTGIR | P43119 | 10/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 7/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.53 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepimostat SCHEMBL872319 | 0.85 | F12 (1.00) | PRSS1F12PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL9825206 | 0.84 | F12 (0.98) | PRSS1F12PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL1228902 | 0.83 | PRSS1 (1.00) | PRSS1F12PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL15536391 | 0.83 | PRSS1 (1.00) | PRSS1F12PRSS2PRSS3F2 | |
| Sepimostat SCHEMBL29406588 | 0.83 | PRSS1 (1.00) | PRSS1F12PRSS2PRSS3F2 | |
| SCHEMBL6158402 | 0.73 | PTGIR (0.63) | PRSS1F12PRSS2PRSS3F2 | |
| SCHEMBL7588328 | 0.72 | ADRA2A (0.64) | PRSS1F12PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL7563216 | 0.70 | PRSS1 (0.68) | PRSS1F12PRSS2PRSS3F2 | |
| SCHEMBL8953899 | 0.70 | ADRA2A (0.79) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL10376201 | 0.70 | PTGIR (0.64) | PRSS1F12PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | PRSS1 545/4885F12 258/4885PRSS2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.